The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
August 14, 2017
View Complete Issue         Table of Contents 2019 
Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
August 14, 2017 (Issue: 1527)
Olaratumab (Lartruvo – Lilly), a platelet-derived growth factor receptor alpha (PDGFR-α) blocking monoclonal antibody, has received accelerated approval from the FDA for use in combination with the anthracycline doxorubicin for first-line...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
Article code: 1527d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.